达雷妥尤单抗对输血相容性试验的影响及改良DTT法消除干扰的研究*

doi:10.3969/j.issn.1671-2587.2026.01.011

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (1): 70-74.DOI: 10.3969/j.issn.1671-2587.2026.01.011

达雷妥尤单抗对输血相容性试验的影响及改良DTT法消除干扰的研究^*

胡艳¹, 卞茂红¹, 鲍静²

¹安徽医科大学第一附属医院输血科;
²安徽医科大学第一附属医院血液科，安徽合肥 230000

收稿日期:2025-07-28 发布日期:2026-02-13
通讯作者: 鲍静，主要从事血液病检验和治疗，（E-mail）doctorbaojing@163.com。
作者简介:胡艳，主要从事临床输血检验和治疗，（E-mail）280934545@qq.com。
基金资助:
*本课题受安徽省高校科研重点项目（No.2022 AH051178）资助

The Effect of Daratumumab on Blood Transfusion Compatibility Testing and the Study on Elimination of Interference Using a Modified DTT Method

HU Yan¹, BIAN Maohong¹, BAO Jing²

¹Department of Blood Transfusion, the First Affiliated Hospital of Anhui Medical University;
²Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei 230000

Received:2025-07-28 Published:2026-02-13

摘要/Abstract

摘要： 目的探究多发性骨髓瘤患者（multiple myeloma, MM）应用达雷妥尤单抗（daratumumab, DARA）治疗后对输血相容性试验的影响，并用改良DTT法消除干扰。方法收集11例在我院应用DARA治疗的MM患者样本，观察DARA治疗对不规则抗体筛查检测和交叉配血试验的影响;用经典DTT法及改良DTT法分别处理抗筛细胞与供者红细胞后，微柱凝胶法进行不规则抗体筛查和交叉配血试验;评估输血效果并观察输血不良反应。结果所有患者经DARA治疗后，微柱凝胶法不规则抗体筛查与交叉配血主侧均呈阳性反应，凝聚胺法检测为阴性反应;改良DTT法处理抗筛细胞与供者红细胞，0.02 mol/L DTT可使微柱凝胶法抗筛与交叉配血主侧均呈阴性反应，可正确检出抗K抗体;输血治疗后患者血红蛋白水平均有不同程度的升高（P<0.05），血清间接胆红素水平无明显变化（P>0.05），表明输血治疗有效，所有患者均未出现严重输血不良反应。结论 DARA治疗可对输血相容性检测产生干扰，可选用改良DTT法进行微柱凝胶法抗筛与交叉配血，保证患者输血的及时性、安全性和有效性。

关键词: 达雷妥尤单抗, 多发性骨髓瘤, 改良DTT法, 微柱凝胶法, 交叉配血

Abstract: Objective To investigate the effect of Daratumumab (DARA) treatment on transfusion compatibility testing in patients with multiple myeloma, and to eliminate interference using a modified DTT method. Methods We collected samples from 11 patients with multiple myeloma treated with DARA in our hospital, and identified the effects of DARA treatment on irregular antibody screening testing and cross matching blood tests. After reagent red cells and donor red blood cells were treated with classical DTT method and modified DTT method respectively, irregular antibody screening and cross matching test were performed by microcolumn gel method. Then we evaluated the effectiveness of blood transfusion and observed adverse reactions of blood transfusion. Results After treatment with DARA, all patients exhibited positive reactions in both irregular antibody screening and the primary cross-matching by microcolumn gel method, while negative reactions by the polybrene method. When the modified DTT method (0.02 mol/L) was used to treat reagent red cells and donor red cells, the results showed negative reactions in both tests by the microcolumn gel method, which could accurately detect anti-K antibodies.The hemoglobin levels of patients increased, and there was no significant change in serum indirect bilirubin before and after transfusion, which indicating transfusion treatment was effective. No serious adverse reactions occurred. Conclusion DARA treatment could interfere transfusion compatibility tests. Modified DTT method would be an optional method for irregular antibody screening and cross matching.

Key words: Daratumumab, Multiple myeloma, Modified DTT method, Microcolumn gel method, Cross matching

中图分类号:

R457.1

胡艳, 卞茂红, 鲍静. 达雷妥尤单抗对输血相容性试验的影响及改良DTT法消除干扰的研究^*[J]. 临床输血与检验, 2026, 28(1): 70-74.

HU Yan, BIAN Maohong, BAO Jing. The Effect of Daratumumab on Blood Transfusion Compatibility Testing and the Study on Elimination of Interference Using a Modified DTT Method[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(1): 70-74.

参考文献

[1] VRTIS M C.Multiple myeloma[J]. Home Healthc NOW,2024,42(3):140-149.
[2] PALUMBO A,CHANAN-KHAN A,WEISEL K,et al.Daratumumab,bortezomib,and dexamethasone for multiple myeloma[J]. N Engl J Med,2016,375(8):754-766.
[3] AUNG F,SPENCER J,POTTER D,et al.Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody[J]. Transfusion,2022,62(8):1511-1518.
[4] 中国医师协会血液科医师分会,中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志,2022,61(5):480-487.
[5] GOZZETTI A,CIOFINI S,SIMONCELLI M,et al.Anti CD38 monoclonal antibodies for multiple myeloma treatment[J]. Hum Vaccin Immunother,2022,18(5): 2052658.
[6] WU H T,ZHAO X Y.Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies[J]. Int J Biol Sci,2022,18(5):1974-1988.
[7] JIAO Y,YI M,XU L P,et al.CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers[J]. Expert Opin Investig Drugs,2020,29(11): 1295-1308.
[8] DU C H,SUI W J,HUANG H T,et al.Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment[J]. Leuk Res,2022,122:106953.
[9] OOSTENDORP M,LAMMERTS VAN BUEREN J J,DOSHI P,et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy[J]. Transfusion,2015,55(6 Pt 2):1555-1562.
[10] FENG C C,CHANG C W,LIEN Z Y,et al.Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test[J]. J Clin Lab Anal,2023,37(8):e24891.
[11] Fung M K,等. AABB技术手册[M]. 18版. 桂嵘,等主译. 长沙:中南大学出版社,2019.
[12] 黎裕元,张玲,蔡葵,等. 改良DTT法用于减少达雷妥尤单抗对血清学检测造成的干扰[J]. 中国实验血液学杂志, 2023,31(5):1543-1549.
[13] 赫喜荣,张凡,王娜,等. 0.01 mol/L DTT处理意外抗体筛查试剂红细胞以消除达雷妥尤单抗干扰及临床适应性研究[J]. 临床输血与检验,2022,24(6):749-753.
[14] LI Y Y,LI C Y,ZHANG L,et al.Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol (DTT) for pre-transfusion testing of patients receiving anti-CD38 therapy,daratumumab[J]. Hematology,2023,28(1):2186037.
[15] HOSOKAWA M,KASHIWAGI H,NAKAYAMA K,et al.Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)[J]. Transfusion,2018,58(12):3003-3013.
[16] IZAGUIRRE E C,DEL MAR LUIS-HIDALGO M,GONZÁLEZ L L,et al. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing[J]. Blood Transfus, 2020,18(4):290-294.
[17] JONES A D,MOAYERI M,NAMBIAR A.Impact of new myeloma agents on the transfusion laboratory[J]. Pathology,2021,53(3):427-437.

达雷妥尤单抗对输血相容性试验的影响及改良DTT法消除干扰的研究^*

The Effect of Daratumumab on Blood Transfusion Compatibility Testing and the Study on Elimination of Interference Using a Modified DTT Method

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	田雪, 徐华, 许亚莉, 王红, 张良子, 褚晓月, 王锦, 吴大洲. 新生儿静注人免疫球蛋白导致溶血性贫血2例^*[J]. 临床输血与检验, 2025, 27(6): 845-848.
[2]	魏华, 赵静雅, 富文达, 凤琼, 穆士杰, 杨龙飞. MOLP8细胞系用于消除达雷妥尤单抗对输血前相容性检测造成的干扰^*[J]. 临床输血与检验, 2025, 27(5): 643-648.
[3]	王丹婷, 龙红惠, 牛迎迎, 黄春妍. 微柱凝胶法交叉配血次侧不合的原因探讨及临床意义分析[J]. 临床输血与检验, 2024, 26(6): 750-754.
[4]	陈旭升, 杨永涛. 静脉输注丙种球蛋白对非新生儿溶血患儿交叉配血的影响[J]. 临床输血与检验, 2023, 25(6): 749-752.
[5]	陈婷婷, 赵丽坤, 卓海龙, 骆群. ABO不同血型在不同保存期内CD38的表达[J]. 临床输血与检验, 2023, 25(5): 613-618.
[6]	刘慧, 卓海龙, 骆群. 达雷妥尤单抗对凝聚胺技术检出IgG抗D抗体的影响[J]. 临床输血与检验, 2023, 25(5): 625-630.
[7]	张静, 王素玲, 乔芳, 赵佳, 胡光磊, 王振雷. NEC患儿T抗原暴露导致红细胞多凝集现象的鉴定及输血策略[J]. 临床输血与检验, 2023, 25(4): 494-497.
[8]	向倩, 任诗慧, 李晓明. 伊沙佐米治疗多发性骨髓瘤的疗效性与安全性的Meta分析^*[J]. 临床输血与检验, 2023, 25(2): 243-249.
[9]	谢惠益, 周载鑫, 杨玥, 王星怡, 李津杞, 牟显尧, 顾海慧, 钱宝华. 抗-M抗体影响血型鉴定及对临床输血的影响^*[J]. 临床输血与检验, 2022, 24(6): 716-720.
[10]	赫喜荣, 张凡, 王娜, 王璐璐, 刘希曦, 芦宏凯. 0.01 mol/L DTT处理意外抗体筛查试剂红细胞以消除达雷妥尤单抗干扰及临床适应性研究[J]. 临床输血与检验, 2022, 24(6): 749-753.
[11]	宋倩, 马怡然. 自身抗体阳性致配血不相合红细胞输注疗效分析[J]. 临床输血与检验, 2022, 24(5): 588-590.
[12]	刘晓骅, 罗圆圆, 赵嫚, 李族军, 汪德清, 练正秋. 聚乙二醇对微柱凝胶法检测不规则抗体的增强作用分析[J]. 临床输血与检验, 2022, 24(1): 67-70.
[13]	许露萍, 尹俊皓, 王若涵. 罕见抗-Tj^a合并自身抗体致疑难配血分析[J]. 临床输血与检验, 2021, 23(6): 800-802.
[14]	蔡晟阳, 徐军, 陈学军, 尹明伟, 周超, 马继华, 李灵. 浙江地区12月龄内婴儿的ABO血型抗体检出变化初探[J]. 临床输血与检验, 2021, 23(5): 600-603.
[15]	郝萧, 刁雪芹, 鲁雯雯, 张红, 夏小叶. 多次输血产生抗-E、抗-c联合抗-Wr^a抗体致疑难配血一例[J]. 临床输血与检验, 2021, 23(5): 666-667.